
Evolus (EOLS) Stock Forecast & Price Target
Evolus (EOLS) Analyst Ratings
Bulls say
Evolus Inc. reported a significant 29.4% year-over-year increase in total net revenue, totaling $78.9 million in 4Q23, driven largely by higher volumes of its key product, Jeuveau. The company also experienced impressive account growth, with approximately 830 new accounts purchasing Jeuveau in the quarter, surpassing the quarterly average by 20%. Additionally, the imminent launch of the Evolysse fillers, projected to contribute 8-10% to total revenue for FY 2025, reflects a strong strategic position, bolstered by favorable market trends among younger consumers toward aesthetic treatments.
Bears say
Evolus Inc. reported a 4Q23 GAAP net loss of $6.8 million, translating to a loss per share of $0.11, which exceeded internal estimates and fell short of the consensus forecast. The company also faces significant operational challenges, including reliance on third-party suppliers for its product Jeuveau, contributing to a heightened risk of supply chain disruptions and increased operating expenses. Additionally, competitive pressures in the cash-pay aesthetic market, alongside potential financing risks and the lingering effects of COVID-19, further exacerbate Evolus's challenges, creating a negative outlook for its stock performance.
This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.
Evolus (EOLS) Analyst Forecast & Price Prediction
Start investing in Evolus (EOLS)
Order type
Buy in
Order amount
Est. shares
0 shares